- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: Left common carotid artery.
Displaying page 1 of 1.
EudraCT Number: 2012-001582-33 | Sponsor Protocol Number: Er-01-Perf-Stroke | Start Date*: 2012-09-19 |
Sponsor Name:University Hospital Erlangen | ||
Full Title: Intraindividual cross-over comparison of Gadobutrol and Gadoterate enhanced combined DSC-MR-Perfusion and MR-Angiography in patients with cerebrovascular disease | ||
Medical condition: Patients with high grade carotid artery stenosis or acute cerebral ischemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001913-13 | Sponsor Protocol Number: 0524A-041 | Start Date*: 2006-11-29 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Art... | |||||||||||||
Medical condition: heterozygous familial hypercholesterolemia (HeFH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002796-28 | Sponsor Protocol Number: CEASESTIFFNESS | Start Date*: 2016-04-12 |
Sponsor Name:University Medical Center Groningen (UMCG) | ||
Full Title: The Clinical Efficacy And Subclinical Effects on arterial STIFFNESS of bosentan therapy added to usual care in patients with systemic sclerosis with digital ulcers. | ||
Medical condition: Systemic sclerosis (SSc) is characterized by skin fibrosis and visceral disease, mainly of the lungs, kidneys and the heart, accompanied by microvascular damage ultimately leading to digital ischem... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003818-26 | Sponsor Protocol Number: K-877-302 | Start Date*: 2017-03-16 | |||||||||||
Sponsor Name:Kowa Research Institute, Inc. | |||||||||||||
Full Title: Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabeTes (PROMINENT) | |||||||||||||
Medical condition: Reduction of cardiovascular events in patients with Type II Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) NL (Prematurely Ended) BG (Prematurely Ended) DE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002636-25 | Sponsor Protocol Number: RG_13-013NS | Start Date*: 2013-09-11 |
Sponsor Name:University of Birmingham | ||
Full Title: A Randomised Multicentre Open Label Blinded End Point Trial to Compare the Effects of Spironolactone to Chlortalidone on Left Ventricular Mass and Arterial Stiffness in Stage 3 Chronic Kidney Disease | ||
Medical condition: The condition under investigation is the disease changes that occur in patients with mild kidney disease that cause them to have a high rate of diseases such as heart failure, rhythm disturbance an... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
